J&J’s Rybrevant Earns First-Line NSCLC Approval in Canada, a Milestone for EGFR Exon 20 Patients
Johnson & Johnson (J&J; NYSE: JNJ) has announced that Rybrevant (amivantamab) has received its first...
Drug
Sanofi’s RSV Preventative Therapy Beyfortus Launches in China
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has announced the commercial launch of Beyfortus...
Full-Life Technologies’ ²²⁵Ac-FL-020 Earns FDA Fast-Track Status for mCRPC
Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and...
HutchMed’s Tazverik for Follicular Lymphoma Accepted for Review by China’s NMPA
HutchMed (NASDAQ: HCM), a China-based biopharmaceutical company, has announced that the National Medical Products Administration...
LG Chem and Yifan Pharmaceutical Launch Hyruan ONE for Knee Osteoarthritis in China
LG Chem, a leading chemical company based in South Korea, and Yifan Pharmaceutical Co., Ltd...
AstraZeneca’s Voydeya Receives South Korean Approval for PNH Treatment
AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical giant, has reportedly secured market approval in South...
Astellas Pharma’s Xtandi Secures Third Market Approval in China for Prostate Cancer Treatment
Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced that it has...
Eslicarbazepine Makes First Appearance in China at Sichuan University’s West China Lecheng Hospital
Eslicarbazepine, a voltage-gated sodium channel blocker, co-developed by Bial-Portela, Eisai, and Sumitomo Pharma, was first...
China’s Jiangsu Hengrui First to Market Generic Exparel in the US with FDA ANDA Approval
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Shanghai Henlius Biotech Advances Serplulimab Phase III Trial for First-Line Metastatic Colorectal Cancer
Shanghai Henlius Biotech Inc. (HKG: 2696), a biopharmaceutical company based in China, has announced that...
MabPharm’s Biosimilar Infliximab CMAB807 Receives Market Approval in Peru
MabPharm Ltd (HKG: 2181), a biosimilar specialist in monoclonal antibody (mAb) based in Taizhou, has...
Legend Biotech’s Carvykti Shows Significant Overall Survival Improvement in Phase III CARTITUDE-4 Study
Legend Biotech Corporation (NASDAQ: LEGN) has announced positive results from the CARTITUDE-4 study, a global,...
Lilly’s Kisunla Poised to Shake Up Alzheimer’s Treatment Market with FDA Approval
Eli Lilly & Co. (NYSE: LLY) has announced that the U.S. Food and Drug Administration...
Johnson & Johnson’s Talvey Gets Green Light in South Korea for Multiple Myeloma
Johnson & Johnson (J&J; NYSE: JNJ) has announced that its subsidiary Janssen Korea has received...
Eli Lilly & Co. Strikes Deal for Radionetics’ GPCR-Targeted Radiopharmaceuticals
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the US, has...
Boehringer Ingelheim Initiates Clinical Trial for Novel Anti-Obesity Drug
Boehringer Ingelheim (BI), a German pharmaceutical company, has announced the commencement of clinical development for...
Tracon Pharmaceuticals Halts Development of Envafolimab After Clinical Trial Failure
Tracon Pharmaceuticals (OTCMKTS: TCON), a US-based biopharmaceutical company, has decided to cease development of its...
Innovent Biologics Presents Positive Phase I Results for IBI343 at ESMO GI Congress 2024
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...
Yantai Dongcheng Pharmaceutical’s 177LuLNC1011 Gets FDA Green Light for Prostate Cancer Clinical Trial
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a pharmaceutical company based in China, has...
SCG Cell Therapy Receives FDA Approval for HPV-Targeted SCG142 Clinical Trial
SCG Cell Therapy Pte. Ltd, a Singapore-headquartered biotechnology company with a presence in Shanghai, has...